Risankizumab-Rzaa
Brand name: Skyrizi Pen
Rank #72 of 500 drugs by total cost
$259.7M
Total Cost
12,539
Total Claims
$259.7M
Total Cost
709
Prescribers
$21K
Cost per Claim
639
Beneficiaries
31,084
30-Day Fills
$366K
Avg Cost/Provider
18
Avg Claims/Provider
About Risankizumab-Rzaa
Risankizumab-Rzaa (sold as Skyrizi Pen) was prescribed 12,539 times by 709 Medicare Part D providers in 2023, costing the program $259.7M. At $21K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 69 | Elexacaftor/Tezacaftor/Ivacaft (Trikafta) | $269.3M | 9,821 |
| 70 | Immune Globul G/Gly/Iga Avg 46 (Gamunex-C) | $266.5M | 27,501 |
| 71 | Rosuvastatin Calcium (Rosuvastatin Calcium) | $264.9M | 11,259,701 |
| 72 | Risankizumab-Rzaa (Skyrizi Pen) | $259.7M | 12,539 |
| 73 | Venetoclax (Venclexta) | $259.6M | 28,191 |
| 74 | Zanubrutinib (Brukinsa) | $256.8M | 19,239 |
| 75 | Metoprolol Succinate (Metoprolol Succinate) | $256.3M | 12,847,535 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology